SCHEMBL5285705

SCHEMBL5285705

CCN(CC(=O)O)S(=O)(=O)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.63
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
KEAP1 Q14145 2/20 0.55
LMNA P02545 3/20 0.54
HTT P42858 2/20 0.54
NFE2L2 Q16236 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 2/20 0.51
TSHR P16473 2/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
MMP14 P50281 1/20 0.50
MMP16 P51512 1/20 0.50
CNR2 P34972 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5284924 0.86 MAPK1 (0.68) MAPK1KEAP1NFE2L2SMN1; SMN2
SCHEMBL9972493 0.86 KEAP1 (0.62) MAPK1KMT2AALDH1A1KEAP1LMNA
SCHEMBL11802279 0.85 MAPK1 (0.71) MAPK1ALDH1A1KEAP1NFE2L2MMP1
SCHEMBL13267917 0.85 MAPK1 (0.71) MAPK1ALDH1A1KEAP1NFE2L2SMN1; SMN2
SCHEMBL15720060 0.85 KMT2A (0.57) MAPK1KMT2AALDH1A1KEAP1LMNA
SCHEMBL2058156 0.85 LMNA (0.70) KMT2AALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL13286823 0.81 LMNA (0.61) MAPK1KMT2AALDH1A1LMNAHTT
SCHEMBL5295487 0.81 TAS2R14 (0.64) MAPK1KMT2AALDH1A1KEAP1MEN1
SCHEMBL17567120 0.79 LMNA (0.59) KMT2AALDH1A1KDM4ELMNAHTT
SCHEMBL12668398 0.79 HPGD (0.58) MAPK1KMT2AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MAPK1 3183/4885KMT2A 4422/4885ALDH1A1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.